Without An Alzheimer’s Blockbuster, Biogen Is A Ship Without A Growth Rudder

Lecanemab Phase III Readout Next Major Milestone

 
• By Mandy Jackson

In addition to its uncertain attempt at near-term revenue growth with Eisai-partnered lecanemab, Biogen recently ended multiple R&D programs and will pay $900m to settle a whistleblower lawsuit.

Sailing yacht control wheel and implement
Biogen is trying to navigate its way back to revenue growth • Source: Shutterstock

More from Strategy

More from Business